论文部分内容阅读
目的 探讨HSP70和HLA -DR抗原表达与临床和预后的关系。方法 采用免疫组织化学DakoEnvision法检测 5 0例鼻咽癌组织中HSP70和HLA -DR抗原表达情况 ,并分析二者表达与鼻咽癌临床病理与预后的关系。结果 HSP70和HLA-DR阳性率分别为 72 % (36 / 5 0 )和 5 6 % (2 8/ 5 0 ) ,HSP70和HLA -DR抗原的表达与组织学分类 ,临床分期无关 (P >0 .0 5 ) ,与预后有关。HSP70 (- ) /HLA -DR(+)患者 7年生存率明显高于其他患者。结论 HSP70和HLA -DR抗原联合检测有助于评估病人预后。
Objective To investigate the relationship between HSP70 and HLA-DR antigen expression and clinical and prognosis. Methods Immunohistochemical DakoEnvision method was used to detect the expression of HSP70 and HLA-DR antigen in 50 cases of nasopharyngeal carcinoma. The relationship between the expression of HSP70 and HLA-DR antigen and the clinicopathological features and prognosis of nasopharyngeal carcinoma were analyzed. Results The positive rates of HSP70 and HLA-DR were 72% (36/50) and 56% (28/50) respectively. The expression of HSP70 and HLA-DR antigen was not related to histological classification and clinical stage (P> 0) .0 5), and prognosis. The 7-year survival rate of HSP70 (-) / HLA-DR (+) patients was significantly higher than that of other patients. Conclusions The combined detection of HSP70 and HLA-DR antigen is helpful to evaluate the prognosis of patients.